Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies

John L. Marshall, Neelesh Bangalore, Dorraya El-Ashry, Yair Fuxman, Michael Johnson, Brian Norris, Michael Oberst, Elizabeth Ness, Slawomir Wojtowicz-Praga, Pankaj Bhargava, Naiyer Rizvi, Said Baidas, Michael J. Hawkins

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: Bryostatin-1 is a compound known to inhibit protein kinase C expression. Clinical trials have focused on administration schedules ranging from 1 hour to 72 hour infusions. Preclinical data suggest that the down regulation of the target PKC occurs only as long as the drug is being infused. Therefore we performed a phase 1 clinical trial to determine the safety and recommended dose of prolonged infusion Bryostatin-1. Experimental Design: Patients with advanced metastatic cancer were enrolled in this traditional phase 1 clinical trial utilizing prolonged infusion Bryostatin-1. The administration of Bryostatin-1 was initially begun at 96 hours and extended to 14 days. Doses were escalated using the 96 hour infusion time and then duration of infusion was increased. All patients underwent extensive sampling for determination of PKC levels as well as other key biologic end points. The determination of maximum tolerated dose and recommended phase two dose were based on toxicity. Results: 38 patients were enrolled in the study. The recommended phase two doses were 24 mcg/m2 over five days, 16 mcg/m2 over six days and 8 mcg/m2 over 14 days. At the higher dose levels we demonstrated consistent down regulation of PKC-α. This was not observed at the low dose level. Toxicities were limited to myalgias and fatigue and were dose-related. The results of downstream signaling effects were less clear. MMP expression was not altered by treatment with Bryostatin-1. Only limited evidence for alterations in PKC activity as measured by expression of phosphorylated MAPK was observed. No objective responses were observed with five patients having prolonged stabilization of disease. Conclusions: Bryostatin-1 is safely administered over prolonged infusion schedules. There appears to be a dose response for PKC inhibition. Bryostatin-1 is a complicated compound as is the target PKC and its related signaling pathways. There is only limited clinical activity with this compound as a single agent; future studies should focus on combinations with other cytotoxics or targeted therapies.

Original languageEnglish
Pages (from-to)409-416
Number of pages8
JournalCancer Biology and Therapy
Volume1
Issue number4
DOIs
StatePublished - Jul 1 2002
Externally publishedYes

Fingerprint

Neoplasms
Clinical Trials, Phase I
Appointments and Schedules
Down-Regulation
Maximum Tolerated Dose
Myalgia
bryostatin 1
Matrix Metalloproteinases
Protein Kinase C
Fatigue
Research Design
Clinical Trials
Safety
Therapeutics
Pharmaceutical Preparations

Keywords

  • Bryostatin-1
  • Phase I
  • Protein kinase C

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Marshall, J. L., Bangalore, N., El-Ashry, D., Fuxman, Y., Johnson, M., Norris, B., ... Hawkins, M. J. (2002). Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies. Cancer Biology and Therapy, 1(4), 409-416. https://doi.org/10.4161/cbt.1.4.17

Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies. / Marshall, John L.; Bangalore, Neelesh; El-Ashry, Dorraya; Fuxman, Yair; Johnson, Michael; Norris, Brian; Oberst, Michael; Ness, Elizabeth; Wojtowicz-Praga, Slawomir; Bhargava, Pankaj; Rizvi, Naiyer; Baidas, Said; Hawkins, Michael J.

In: Cancer Biology and Therapy, Vol. 1, No. 4, 01.07.2002, p. 409-416.

Research output: Contribution to journalArticle

Marshall, JL, Bangalore, N, El-Ashry, D, Fuxman, Y, Johnson, M, Norris, B, Oberst, M, Ness, E, Wojtowicz-Praga, S, Bhargava, P, Rizvi, N, Baidas, S & Hawkins, MJ 2002, 'Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies', Cancer Biology and Therapy, vol. 1, no. 4, pp. 409-416. https://doi.org/10.4161/cbt.1.4.17
Marshall JL, Bangalore N, El-Ashry D, Fuxman Y, Johnson M, Norris B et al. Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies. Cancer Biology and Therapy. 2002 Jul 1;1(4):409-416. https://doi.org/10.4161/cbt.1.4.17
Marshall, John L. ; Bangalore, Neelesh ; El-Ashry, Dorraya ; Fuxman, Yair ; Johnson, Michael ; Norris, Brian ; Oberst, Michael ; Ness, Elizabeth ; Wojtowicz-Praga, Slawomir ; Bhargava, Pankaj ; Rizvi, Naiyer ; Baidas, Said ; Hawkins, Michael J. / Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies. In: Cancer Biology and Therapy. 2002 ; Vol. 1, No. 4. pp. 409-416.
@article{c4bb542f66774e7bbd0276cc67f2d37a,
title = "Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies",
abstract = "Purpose: Bryostatin-1 is a compound known to inhibit protein kinase C expression. Clinical trials have focused on administration schedules ranging from 1 hour to 72 hour infusions. Preclinical data suggest that the down regulation of the target PKC occurs only as long as the drug is being infused. Therefore we performed a phase 1 clinical trial to determine the safety and recommended dose of prolonged infusion Bryostatin-1. Experimental Design: Patients with advanced metastatic cancer were enrolled in this traditional phase 1 clinical trial utilizing prolonged infusion Bryostatin-1. The administration of Bryostatin-1 was initially begun at 96 hours and extended to 14 days. Doses were escalated using the 96 hour infusion time and then duration of infusion was increased. All patients underwent extensive sampling for determination of PKC levels as well as other key biologic end points. The determination of maximum tolerated dose and recommended phase two dose were based on toxicity. Results: 38 patients were enrolled in the study. The recommended phase two doses were 24 mcg/m2 over five days, 16 mcg/m2 over six days and 8 mcg/m2 over 14 days. At the higher dose levels we demonstrated consistent down regulation of PKC-α. This was not observed at the low dose level. Toxicities were limited to myalgias and fatigue and were dose-related. The results of downstream signaling effects were less clear. MMP expression was not altered by treatment with Bryostatin-1. Only limited evidence for alterations in PKC activity as measured by expression of phosphorylated MAPK was observed. No objective responses were observed with five patients having prolonged stabilization of disease. Conclusions: Bryostatin-1 is safely administered over prolonged infusion schedules. There appears to be a dose response for PKC inhibition. Bryostatin-1 is a complicated compound as is the target PKC and its related signaling pathways. There is only limited clinical activity with this compound as a single agent; future studies should focus on combinations with other cytotoxics or targeted therapies.",
keywords = "Bryostatin-1, Phase I, Protein kinase C",
author = "Marshall, {John L.} and Neelesh Bangalore and Dorraya El-Ashry and Yair Fuxman and Michael Johnson and Brian Norris and Michael Oberst and Elizabeth Ness and Slawomir Wojtowicz-Praga and Pankaj Bhargava and Naiyer Rizvi and Said Baidas and Hawkins, {Michael J.}",
year = "2002",
month = "7",
day = "1",
doi = "10.4161/cbt.1.4.17",
language = "English",
volume = "1",
pages = "409--416",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "4",

}

TY - JOUR

T1 - Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies

AU - Marshall, John L.

AU - Bangalore, Neelesh

AU - El-Ashry, Dorraya

AU - Fuxman, Yair

AU - Johnson, Michael

AU - Norris, Brian

AU - Oberst, Michael

AU - Ness, Elizabeth

AU - Wojtowicz-Praga, Slawomir

AU - Bhargava, Pankaj

AU - Rizvi, Naiyer

AU - Baidas, Said

AU - Hawkins, Michael J.

PY - 2002/7/1

Y1 - 2002/7/1

N2 - Purpose: Bryostatin-1 is a compound known to inhibit protein kinase C expression. Clinical trials have focused on administration schedules ranging from 1 hour to 72 hour infusions. Preclinical data suggest that the down regulation of the target PKC occurs only as long as the drug is being infused. Therefore we performed a phase 1 clinical trial to determine the safety and recommended dose of prolonged infusion Bryostatin-1. Experimental Design: Patients with advanced metastatic cancer were enrolled in this traditional phase 1 clinical trial utilizing prolonged infusion Bryostatin-1. The administration of Bryostatin-1 was initially begun at 96 hours and extended to 14 days. Doses were escalated using the 96 hour infusion time and then duration of infusion was increased. All patients underwent extensive sampling for determination of PKC levels as well as other key biologic end points. The determination of maximum tolerated dose and recommended phase two dose were based on toxicity. Results: 38 patients were enrolled in the study. The recommended phase two doses were 24 mcg/m2 over five days, 16 mcg/m2 over six days and 8 mcg/m2 over 14 days. At the higher dose levels we demonstrated consistent down regulation of PKC-α. This was not observed at the low dose level. Toxicities were limited to myalgias and fatigue and were dose-related. The results of downstream signaling effects were less clear. MMP expression was not altered by treatment with Bryostatin-1. Only limited evidence for alterations in PKC activity as measured by expression of phosphorylated MAPK was observed. No objective responses were observed with five patients having prolonged stabilization of disease. Conclusions: Bryostatin-1 is safely administered over prolonged infusion schedules. There appears to be a dose response for PKC inhibition. Bryostatin-1 is a complicated compound as is the target PKC and its related signaling pathways. There is only limited clinical activity with this compound as a single agent; future studies should focus on combinations with other cytotoxics or targeted therapies.

AB - Purpose: Bryostatin-1 is a compound known to inhibit protein kinase C expression. Clinical trials have focused on administration schedules ranging from 1 hour to 72 hour infusions. Preclinical data suggest that the down regulation of the target PKC occurs only as long as the drug is being infused. Therefore we performed a phase 1 clinical trial to determine the safety and recommended dose of prolonged infusion Bryostatin-1. Experimental Design: Patients with advanced metastatic cancer were enrolled in this traditional phase 1 clinical trial utilizing prolonged infusion Bryostatin-1. The administration of Bryostatin-1 was initially begun at 96 hours and extended to 14 days. Doses were escalated using the 96 hour infusion time and then duration of infusion was increased. All patients underwent extensive sampling for determination of PKC levels as well as other key biologic end points. The determination of maximum tolerated dose and recommended phase two dose were based on toxicity. Results: 38 patients were enrolled in the study. The recommended phase two doses were 24 mcg/m2 over five days, 16 mcg/m2 over six days and 8 mcg/m2 over 14 days. At the higher dose levels we demonstrated consistent down regulation of PKC-α. This was not observed at the low dose level. Toxicities were limited to myalgias and fatigue and were dose-related. The results of downstream signaling effects were less clear. MMP expression was not altered by treatment with Bryostatin-1. Only limited evidence for alterations in PKC activity as measured by expression of phosphorylated MAPK was observed. No objective responses were observed with five patients having prolonged stabilization of disease. Conclusions: Bryostatin-1 is safely administered over prolonged infusion schedules. There appears to be a dose response for PKC inhibition. Bryostatin-1 is a complicated compound as is the target PKC and its related signaling pathways. There is only limited clinical activity with this compound as a single agent; future studies should focus on combinations with other cytotoxics or targeted therapies.

KW - Bryostatin-1

KW - Phase I

KW - Protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=0345459958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345459958&partnerID=8YFLogxK

U2 - 10.4161/cbt.1.4.17

DO - 10.4161/cbt.1.4.17

M3 - Article

C2 - 12432257

AN - SCOPUS:0345459958

VL - 1

SP - 409

EP - 416

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 4

ER -